"2025 was a landmark year for Citius Oncology. With the U.S. commercial launch of LYMPHIR now underway, we have shifted from a pre-revenue to a revenue generating company," said Leonard Mazur, Chairman and CEO of Citius Oncology and parent company Citius Pharmaceuticals. "Our focus now is on driving adoption, delivering value to patients, and realizing the full commercial potential of our first-in-class therapy. We intend to leverage our advanced AI-driven analytics to refine targeting, optimize field execution, and maximize commercial efficiency. In parallel, we have also begun laying the groundwork for international access with key distribution partners spanning 19 markets in Southern Europe and the Middle East via Named Patient Programs. These foundational efforts position us to scale and deliver sustained value to patients and shareholders alike."
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast CTOR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CTOR is 6.00 USD with a low forecast of 6.00 USD and a high forecast of 6.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.100
Low
6.00
Averages
6.00
High
6.00
Current: 1.100
Low
6.00
Averages
6.00
High
6.00
Maxim
Michael Okunewitch
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Michael Okunewitch
Price Target
$6
AI Analysis
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim analyst Michael Okunewitch upgraded Citius Oncology to Buy from Hold with a $6 price target.
Maxim
Hold
to
Buy
upgrade
$6
2025-09-23
Reason
Maxim
Price Target
$6
2025-09-23
upgrade
Hold
to
Buy
Reason
Maxim upgraded Citius Oncology to Buy from Hold with a $6 price target. The company has taken key steps to address its capital needs and now should have a path to launching Lymphir in Q4 of this year, which is a \"key event\" for Citius, the analyst tells investors in a research note. Cutaneous T-cell lymphoma is a relatively small and concentrated market, which should support pricing of about $300K per course of treatment, and the firm believes that sales could \"ramp quickly\" in 2026, the firm added.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for CTOR
Unlock Now
Maxim
Buy
to
Hold
downgrade
2025-05-23
Reason
Maxim
Price Target
2025-05-23
downgrade
Buy
to
Hold
Reason
Maxim downgraded Citius Oncology to Hold from Buy.
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
